These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Statins: the next anti-endotoxin. Kruger PS Crit Care Resusc; 2006 Sep; 8(3):223-6. PubMed ID: 16930109 [TBL] [Abstract][Full Text] [Related]
4. Functional interplay between the macrophage scavenger receptor class B type I and pitavastatin (NK-104). Han J; Parsons M; Zhou X; Nicholson AC; Gotto AM; Hajjar DP Circulation; 2004 Nov; 110(22):3472-9. PubMed ID: 15557368 [TBL] [Abstract][Full Text] [Related]
10. Lipid composition and lipopolysaccharide binding capacity of lipoproteins in plasma and lymph of patients with systemic inflammatory response syndrome and multiple organ failure. Levels JH; Lemaire LC; van den Ende AE; van Deventer SJ; van Lanschot JJ Crit Care Med; 2003 Jun; 31(6):1647-53. PubMed ID: 12794399 [TBL] [Abstract][Full Text] [Related]
11. Pleiotropic effects of statins and related pharmacological experimental approaches. Alegret M; Silvestre JS Methods Find Exp Clin Pharmacol; 2006 Nov; 28(9):627-56. PubMed ID: 17200729 [TBL] [Abstract][Full Text] [Related]
12. (TTA)n polymorphism in 3-hydroxy-3-methylglutaryl-coenzyme A and response to atorvastatin in coronary artery disease patients. Noriega V; Pennanen C; Sánchez MP; Chiong M; Llancaqueo M; Lavandero S; Prieto JC Basic Clin Pharmacol Toxicol; 2009 Mar; 104(3):211-5. PubMed ID: 19067673 [TBL] [Abstract][Full Text] [Related]
13. [Pleiotrophic effect of statins (3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors)]. Igel M; Sudhop T; von Bergmann K Arzneimittelforschung; 2003; 53(8):545-53. PubMed ID: 13677244 [TBL] [Abstract][Full Text] [Related]
14. Lipid-lowering and antiatherosclerotic effect of NK-104, a potent 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in Watanabe heritable hyperlipidemic rabbits. Suzuki H; Yamazaki H; Aoki T; Kojima J; Tamaki T; Sato F; Kitahara M; Saito Y Arzneimittelforschung; 2000 Nov; 50(11):995-1003. PubMed ID: 11187394 [TBL] [Abstract][Full Text] [Related]
15. Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting. Bullano MF; Wertz DA; Yang GW; Kamat S; Borok GM; Gandhi S; McDonough KL; Willey VJ Pharmacotherapy; 2006 Apr; 26(4):469-78. PubMed ID: 16553504 [TBL] [Abstract][Full Text] [Related]
16. Association of statins and diabetes mellitus. Hagedorn J; Arora R Am J Ther; 2010; 17(2):e52-5. PubMed ID: 20019585 [TBL] [Abstract][Full Text] [Related]
17. Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering. Pedersen TR Am J Cardiovasc Drugs; 2010; 10 Suppl 1():10-7. PubMed ID: 21391729 [TBL] [Abstract][Full Text] [Related]
18. Fluvastatin prevents renal injury and expression of lactin-like oxidized low-density lipoprotein receptor-1 in rabbits with hypercholesterolemia. Yu YH; Wang Y; Dong B; Sun SZ; Chen Y; Meng XH; Liu ZZ Chin Med J (Engl); 2005 Apr; 118(8):621-6. PubMed ID: 15899115 [TBL] [Abstract][Full Text] [Related]